Sep 6–7 produced zero deal events, zero FDA approvals, and zero market-moving tickers — but 12 Phase 2/3 readouts are queued inside the next 90 days. The calendar is the only active dataset this window.
TL;DR — No deals, no approvals, and no price moves in Sep 6–7. The only computed signal is 0 FDA approvals after a four-day holiday weekend; the FDA’s last novel-drug action was 3 Sep 2026, so the absence reads as noise, not a reliable PDUFA batch predictor. Twelve Phase 2/3 readouts sit within 90 days; 10 of them are Phase 3 and the top three by score enroll 779 patients combined.
Deals
No qualifying deal events surfaced in the collection window.
Approvals
openFDA recorded no approvals in this window.
Readout Calendar
Table 1: Phase 2/3 primary completions due in the next 90 days (sorted by pipeline score).
Market Reaction
No market-moving ticker data surfaced in the window.
One Take
The pack’s only computed insight is the absence signal — 0 FDA approvals in a weekday window — but the FDA’s most recent novel-drug approval was 3 Sep 2026 (Zanvastro), so a four-day quiet stretch around Labor Day reads as holiday noise, not a dependable PDUFA batch precursor. That leaves the near-term story in the readout calendar: 12 Phase 2/3 trials complete within 90 days, 10 of them Phase 3, with the top three by score enrolling 779 patients combined. Not all are real catalysts — TAK-788’s first-line EGFR exon 20 record is a stale registry entry after Exkivity’s 2023 withdrawal. My read: until the FDA queue resumes, expect volatility to come from readout dispersion, especially the China-sponsored trials (4 of 12). Conviction: moderate. What would change it: a cluster of approvals this week, or a China Phase 3 readout that materially beats its comparator.
Key takeaways
- Sep 6–7 recorded zero deals, zero FDA approvals, and zero market-moving tickers — the window was data-light.
- 10 of the 12 readouts due within 90 days are Phase 3, with the top three by score enrolling 779 patients combined.
- 4 of the 12 readouts are China-sponsored, including Qilu’s oral semaglutide biosimilar QLG1091 and HengRui’s Lutathera-copy radioligand.
- The 0-approval absence signal is weakened by FDA’s 3 Sep 2026 approval action and the Labor Day holiday; treat it as noise unless a cluster appears this week.
- TAK-788’s top score is a stale registry record, not a near-term catalyst — the real readout dispersion sits lower in the list.
FAQ
Why is TAK-788 still showing a 2026-10-31 primary completion?
EXCLAIM-2 already read out negatively and Takeda voluntarily withdrew Exkivity from the U.S. in October 2023; the EU conditional marketing application was withdrawn in 2022 and the UK conditional authorisation ended in March 2024. The current ClinicalTrials.gov window is a stale registry record, not a new catalyst.
Does the zero-approval window mean a PDUFA batch is coming?
No reliable pattern supports that. The FDA’s last novel-drug approval action was 3 Sep 2026, so a four-day quiet window around Labor Day is better read as noise than as a predictor of a 5-session catch-up cluster.
Which readouts have commercial implications beyond the registry date?
ABBV-RGX-314 in subretinal nAMD anchors AbbVie/REGENXBIO’s lead route for wet AMD; QLG1091 is Qilu’s oral semaglutide biosimilar in a head-to-head against Rybelsus; and HengRui’s 177Lu oxodotreotide could become the first domestic PRRT competitor to Lutathera in China. BL-M07D1, a HER2 ADC with an Ed-04 payload and DAR of 8, is also testing whether it can shift the HER2-positive breast cancer hierarchy versus T-DM1.
Sources
- TAK-788 first-line EGFR exon 20 insertion NSCLC (NCT04129502) — ClinicalTrials.gov
- Capivasertib + fulvestrant in HR+/HER2- breast cancer, Chinese patients (NCT06635447) — ClinicalTrials.gov
- Felzartamab in kidney-transplant AMR (NCT06685757) — ClinicalTrials.gov
- ABBV-RGX-314 subretinal gene therapy for nAMD (NCT04704921) — ClinicalTrials.gov
- Ervebo/Zabdeno Ebola booster vaccines in DRC (NCT06126822) — ClinicalTrials.gov
- Sindilizumab in resectable lung cancer (NCT05116462) — ClinicalTrials.gov
- QLG1091 vs Rybelsus in type 2 diabetes (NCT07487103) — ClinicalTrials.gov
- Ferric carboxymaltose in advanced gastric cancer (NCT05226169) — ClinicalTrials.gov
- BL-M07D1 vs T-DM1 in HER2-positive breast cancer (NCT06316531) — ClinicalTrials.gov
- Melatonin for chronic low back pain (NCT06859957) — ClinicalTrials.gov
- Zibotentan/dapagliflozin in CKD with high proteinuria (NCT06942910) — ClinicalTrials.gov
- 177Lu oxodotreotide in GEP-NETs (NCT05884255) — ClinicalTrials.gov
- Takeda provides update on Exkivity (mobocertinib) — Takeda
- FDA novel drug approvals for 2026 — U.S. FDA
- AbbVie and REGENXBIO announce ABBV-RGX-314 clinical program updates — AbbVie / REGENXBIO
- QLG1091 oral semaglutide biosimilar enters Phase 3 — Sina Finance / PharmCube
- BL-M07D1 Phase 1 data — EBioMedicine (The Lancet)
- HengRui 177Lu oxodotreotide CDE filing — VCBeat
All items above are drawn from first-hand public sources — SEC filings, trial registries, company releases, and regulator records — collected 2026-09-07. Related: Pharma Daily — September 4, 2026.